Novocure Ltd. reported its third quarter 2025 financial results, posting net revenues of $167.2 million, an 8% increase compared to the same period in 2024. The revenue boost was primarily attributed to active patient growth and $3.3 million in exchange rate benefits. As of September 30, 2025, there were 4,416 active patients on therapy. Regional revenue contributions included $96.6 million from the U.S., $20.3 million from Germany, $19.6 million from France, and $9.4 million from Japan, with other active markets contributing $15.7 million. The company also announced that its premarket approval application for Tumor Treating Fields therapy use in pancreatic cancer is under substantive review by the U.S. Food and Drug Administration. A topline data readout from the Phase 3 TRIDENT clinical trial in newly diagnosed glioblastoma is expected in the second quarter of 2026.